Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free GNTA Stock Alerts

Genenta Science (GNTA) Competitors

Genenta Science logo
$0.84 -0.02 (-2.38%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$0.88 +0.04 (+4.31%)
As of 09/11/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

GNTA vs. ACRV, RLYB, ACET, OKYO, and CRDF

Should you buy Genenta Science stock or one of its competitors? Genenta Science's main competitors and comparable companies include Acrivon Therapeutics (ACRV), Rallybio (RLYB), Adicet Bio (ACET), OKYO Pharma (OKYO), and Cardiff Oncology (CRDF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Genenta Science compare to Acrivon Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Genenta Science (NASDAQ:GNTA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 10.5% of Acrivon Therapeutics shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Acrivon Therapeutics and Acrivon Therapeutics both had 1 articles in the media. Acrivon Therapeutics' average media sentiment score of 1.87 equaled Genenta Science'saverage media sentiment score.

Company Overall Sentiment
Acrivon Therapeutics Very Positive
Genenta Science Very Positive

Acrivon Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market. Comparatively, Genenta Science has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acrivon TherapeuticsN/AN/A-$77.90M-$1.88N/A
Genenta ScienceN/AN/A-$7.39MN/AN/A

Acrivon Therapeutics presently has a consensus target price of $13.50, suggesting a potential upside of 575.00%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Acrivon Therapeutics is more favorable than Genenta Science.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acrivon Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Genenta Science's return on equity of 0.00% beat Acrivon Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Acrivon TherapeuticsN/A -70.14% -61.60%
Genenta Science N/A N/A N/A

Summary

Acrivon Therapeutics beats Genenta Science on 5 of the 9 factors compared between the two stocks.

How does Genenta Science compare to Rallybio?

Rallybio (NASDAQ:RLYB) and Genenta Science (NASDAQ:GNTA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Rallybio had 2 more articles in the media than Genenta Science. MarketBeat recorded 3 mentions for Rallybio and 1 mentions for Genenta Science. Genenta Science's average media sentiment score of 1.87 beat Rallybio's score of 1.20 indicating that Genenta Science is being referred to more favorably in the news media.

Company Overall Sentiment
Rallybio Positive
Genenta Science Very Positive

Genenta Science has lower revenue, but higher earnings than Rallybio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rallybio$860K104.22-$8.98M-$4.34N/A
Genenta ScienceN/AN/A-$7.39MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rallybio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Rallybio has a beta of -0.85, indicating that its stock price is 185% less volatile than the broader market. Comparatively, Genenta Science has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

Genenta Science has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Genenta Science's return on equity of 0.00% beat Rallybio's return on equity.

Company Net Margins Return on Equity Return on Assets
Rallybio-911.07% -40.53% -38.13%
Genenta Science N/A N/A N/A

90.3% of Rallybio shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 10.3% of Rallybio shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Genenta Science beats Rallybio on 7 of the 10 factors compared between the two stocks.

How does Genenta Science compare to Adicet Bio?

Adicet Bio (NASDAQ:ACET) and Genenta Science (NASDAQ:GNTA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adicet BioN/AN/A-$116.80M-$11.45N/A
Genenta ScienceN/AN/A-$7.39MN/AN/A

Genenta Science's return on equity of 0.00% beat Adicet Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Adicet BioN/A -74.90% -60.87%
Genenta Science N/A N/A N/A

83.9% of Adicet Bio shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 3.4% of Adicet Bio shares are held by insiders. Comparatively, 29.0% of Genenta Science shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Adicet Bio had 1 more articles in the media than Genenta Science. MarketBeat recorded 2 mentions for Adicet Bio and 1 mentions for Genenta Science. Genenta Science's average media sentiment score of 1.87 beat Adicet Bio's score of 0.93 indicating that Genenta Science is being referred to more favorably in the news media.

Company Overall Sentiment
Adicet Bio Positive
Genenta Science Very Positive

Adicet Bio has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market. Comparatively, Genenta Science has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

Adicet Bio currently has a consensus price target of $46.80, suggesting a potential upside of 391.60%. Given Adicet Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Adicet Bio is more favorable than Genenta Science.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adicet Bio
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
2.88
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Adicet Bio beats Genenta Science on 7 of the 12 factors compared between the two stocks.

How does Genenta Science compare to OKYO Pharma?

Genenta Science (NASDAQ:GNTA) and OKYO Pharma (NASDAQ:OKYO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

In the previous week, OKYO Pharma had 2 more articles in the media than Genenta Science. MarketBeat recorded 3 mentions for OKYO Pharma and 1 mentions for Genenta Science. Genenta Science's average media sentiment score of 1.87 beat OKYO Pharma's score of 0.63 indicating that Genenta Science is being referred to more favorably in the media.

Company Overall Sentiment
Genenta Science Very Positive
OKYO Pharma Positive

Genenta Science has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.03, indicating that its share price is 97% less volatile than the broader market.

OKYO Pharma has a consensus target price of $5.67, suggesting a potential upside of 304.76%. Given OKYO Pharma's stronger consensus rating and higher possible upside, analysts clearly believe OKYO Pharma is more favorable than Genenta Science.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
OKYO Pharma
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by company insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genenta ScienceN/AN/A-$7.39MN/AN/A
OKYO PharmaN/AN/A-$8.95MN/AN/A

Company Net Margins Return on Equity Return on Assets
Genenta ScienceN/A N/A N/A
OKYO Pharma N/A N/A N/A

Summary

OKYO Pharma beats Genenta Science on 5 of the 9 factors compared between the two stocks.

How does Genenta Science compare to Cardiff Oncology?

Cardiff Oncology (NASDAQ:CRDF) and Genenta Science (NASDAQ:GNTA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Cardiff Oncology has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Genenta Science has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 8.8% of Cardiff Oncology shares are owned by insiders. Comparatively, 29.0% of Genenta Science shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Genenta Science has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,885.43%. Genenta Science's return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiff Oncology-7,885.43% -103.10% -75.52%
Genenta Science N/A N/A N/A

Cardiff Oncology currently has a consensus price target of $7.50, suggesting a potential upside of 519.83%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Cardiff Oncology is more favorable than Genenta Science.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiff Oncology
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Cardiff Oncology had 1 more articles in the media than Genenta Science. MarketBeat recorded 2 mentions for Cardiff Oncology and 1 mentions for Genenta Science. Genenta Science's average media sentiment score of 1.87 beat Cardiff Oncology's score of 1.18 indicating that Genenta Science is being referred to more favorably in the news media.

Company Overall Sentiment
Cardiff Oncology Positive
Genenta Science Very Positive

Genenta Science has lower revenue, but higher earnings than Cardiff Oncology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiff Oncology$590K159.54-$45.85M-$0.60N/A
Genenta ScienceN/AN/A-$7.39MN/AN/A

Summary

Cardiff Oncology beats Genenta Science on 7 of the 13 factors compared between the two stocks.

Get Genenta Science News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNTA vs. The Competition

Export
MetricGenenta ScienceBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$19.84M$3.86B$7.17B$12.85B
Dividend YieldN/A3.66%2.57%11.71%
P/E RatioN/A14.18274.9425.33
Price / SalesN/A1,375.01685.45111.12
Price / CashN/A106.5076.6551.52
Price / Book0.6515.1210.336.20
Net Income-$7.39M-$22.86M$3.50B$358.50M
7 Day Performance-12.43%-4.34%-3.32%-2.35%
1 Month Performance-35.32%-0.02%-0.41%-2.77%
1 Year Performance-71.84%40.64%19.21%7.63%

Genenta Science Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNTA
Genenta Science
1.1702 of 5 stars		$0.84
-2.4%		N/A-69.4%$19.84MN/AN/A7
ACRV
Acrivon Therapeutics
4.024 of 5 stars		$2.15
+3.9%		$13.50
+527.9%		+29.0%$92.13MN/AN/A58
RLYB
Rallybio
0.5246 of 5 stars		$16.94
+1.5%		N/A+256.7%$89.95M$860KN/A40
ACET
Adicet Bio
3.4995 of 5 stars		$9.26
flat		$46.80
+405.4%		-32.5%$86.67MN/AN/A90
OKYO
OKYO Pharma
2.9549 of 5 stars		$1.62
+7.3%		$5.67
+249.8%		-35.5%$85.02MN/AN/A7

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GNTA) was last updated on 9/12/2026 by MarketBeat.com Staff.
From Our Partners
Elon Musk to Trigger Next AI Wave on November 11th?
Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...
Brownstone Research | Sponsoredtc pixel
Gold led me to Mount Rushmore
A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...
Stansberry Research | Sponsoredtc pixel
This 38 Dollar Fund Holds Every Major AI Stock and Pays Weekly
The biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...
Investors Alley | Sponsoredtc pixel
Musk says UBI is coming. I say it's already here.
Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...
Freedom Financial | Sponsoredtc pixel
The income “unicorn” Todd Phillips has been waiting 2 years to see again
Retirement income specialist Todd Phillips once tracked an unusual income vehicle nicknamed the 10.3 percent U...
Eagle Publishing | Sponsoredtc pixel
your job is on the list
The CEO of one of the largest AI labs on earth said it plainly: AI could wipe out half of all entry-level whit...
Behind the Markets | Sponsoredtc pixel
What Is A Roth Conversion, And How Do I Set One Up?
A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...
SmartAsset | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel